CB-13

CB-13
Legal status
Legal status	CA: Schedule II;
Identifiers
	IUPAC name Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone;
JSmol)	Interactive image;
	SMILES c13ccccc1cccc3C(=O)c4ccc(OCCCCC)c2ccccc24;
	InChI InChI=1S/C26H24O2/c1-2-3-8-18-28-25-17-16-24(21-13-6-7-14-22(21)25)26(27)23-15-9-11-19-10-4-5-12-20(19)23/h4-7,9-17H,2-3,8,18H2,1H3; Key:RSUMDJRTAFBISX-UHFFFAOYSA-N;
	(verify)

CB-13 (CRA13, SAB-378)

CB₂ receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,^[2] and has progressed to preliminary human trials.^[3]

Legal Status

As of October 2015 CB-13 is a controlled substance in China.[4]

CB-13 is a Schedule I controlled substance in North Dakota.^[5]

References

S2CID 9198992
.

PMID 17630726
.

S2CID 15150118
.

^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [Notice on Printing and Distributing the "Measures for the Scheduling of Non-Pharmaceutical Narcotic Drugs and Psychotropic Substances"] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.

^ "Schedule 1" (PDF). Sixty-eighth Legislative Assembly of North Dakota. 3 January 2023.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=CB-13&oldid=1209082790"

[1] S2CID 9198992
.

[2] PMID 17630726
.

[pmid19144772-3] S2CID 15150118
.

[4] "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [Notice on Printing and Distributing the "Measures for the Scheduling of Non-Pharmaceutical Narcotic Drugs and Psychotropic Substances"] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.

[5] "Schedule 1" (PDF). Sixty-eighth Legislative Assembly of North Dakota. 3 January 2023.

[2]

[3]

[5]

Legal Status

See also

References